Human & Experimental Toxicology 1994-12-01

Changes in debrisoquine hydroxylation capacity following liver surgery.

SC Mitchell, RR Shah, DG Clements, RL Smith

Index: Hum. Exp. Toxicol. 13(8) , 537-41, (1994)

Full Text: HTML

Abstract

Liver transplantation or the surgical construction of portacaval shunts may radically alter an individual's debrisoquine hydroxylation capacity. Good clinical management should encompass a full awareness of such changing needs and problems in patients who undergo hepatic surgery.

Related Compounds

Related Articles:

Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate.

1999-08-01

[Biochem. Pharmacol. 58(3) , 439-45, (1999)]

Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

1998-03-01

[Br. J. Clin. Pharmacol. 45(3) , 315-7, (1998)]

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.

2005-01-01

[Clin. Chem. Lab Med. 43(3) , 275-9, (2005)]

Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.

1999-01-01

[Chirality 11(7) , 591-7, (1999)]

Debrisoquine hydroxylation in Parkinson's disease.

1992-08-01

[Acta Neurol. Scand 86(2) , 159-64, (1992)]

More Articles...